These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 35195839)

  • 21. Leveraging Genomics for Head and Neck Cancer Treatment.
    Kemmer JD; Johnson DE; Grandis JR
    J Dent Res; 2018 Jun; 97(6):603-613. PubMed ID: 29420101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted molecular imaging of head and neck squamous cell carcinoma: a window into precision medicine.
    Wu J; Yuan Y; Tao XF
    Chin Med J (Engl); 2020 Jun; 133(11):1325-1336. PubMed ID: 32404691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Research Progress in Head and Neck Squamous Cell Carcinoma: Best Abstracts of ICHNO 2015.
    Economopoulou P; Bourhis J; Psyrri A
    Am Soc Clin Oncol Educ Book; 2015; ():e323-8. PubMed ID: 25993192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing.
    Tillman BN; Yanik M; Birkeland AC; Liu CJ; Hovelson DH; Cani AK; Palanisamy N; Carskadon S; Carey TE; Bradford CR; Tomlins SA; McHugh JB; Spector ME; Brenner JCh
    Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E1646-52. PubMed ID: 26849095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC).
    Economopoulou P; Spathis A; Kotsantis I; Maratou E; Anastasiou M; Moutafi MK; Kirkasiadou M; Pantazopoulos A; Giannakakou M; Edelstein DL; Sloane H; Fredebohm J; Jones FS; Kyriazoglou A; Gavrielatou N; Foukas P; Panayiotides I; Psyrri A
    Oral Oncol; 2023 Apr; 139():106358. PubMed ID: 36871349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Head and neck cancer treatment in the era of molecular medicine.
    Pandruvada S; Kessler R; Thai A
    Adv Cancer Res; 2023; 160():205-252. PubMed ID: 37704289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenomic landscape of head and neck squamous cell carcinoma informs precision oncology therapy.
    Gu Z; Yao Y; Yang G; Zhu G; Tian Z; Wang R; Wu Q; Wang Y; Wu Y; Chen L; Wang C; Gao J; Kang X; Zhang J; Wang L; Duan S; Zhao Z; Zhang Z; Sun S
    Sci Transl Med; 2022 Sep; 14(661):eabo5987. PubMed ID: 36070368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma.
    Devaraja K
    Pharmaceut Med; 2019 Aug; 33(4):269-289. PubMed ID: 31933185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "Letter to the Editor: Next-Generation sequencing (NGS) profiling of matched tumor and Circulating Tumor DNA (ctDNA) in Head and Neck Squamous Cell Carcinoma (HNSCC)".
    Meivelu Moovendhan
    Oral Oncol; 2024 Oct; 157():106940. PubMed ID: 39013229
    [No Abstract]   [Full Text] [Related]  

  • 30. A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma.
    Birkeland AC; Swiecicki PL; Brenner JC; Shuman AG
    Expert Rev Precis Med Drug Dev; 2016; 1(4):379-385. PubMed ID: 28251187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Precision medicine in head and neck cancer.
    Kaidar-Person O; Gil Z; Billan S
    Drug Resist Updat; 2018 Sep; 40():13-16. PubMed ID: 30466712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Precision Therapy of Head and Neck Squamous Cell Carcinoma.
    Polverini PJ; D'Silva NJ; Lei YL
    J Dent Res; 2018 Jun; 97(6):614-621. PubMed ID: 29649374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brain metastasis from squamous cell carcinoma of the head and neck: a review of the literature in the genomic era.
    Barrett TF; Gill CM; Miles BA; Iloreta AMC; Bakst RL; Fowkes M; Brastianos PK; Bederson JB; Shrivastava RK
    Neurosurg Focus; 2018 Jun; 44(6):E11. PubMed ID: 29852772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a novel prognostic signature derived from essential genes in head and neck squamous cell carcinoma.
    Dai Y; Yao Q; Wang Z; Diao P; Wang D; Yan E; Wang Y
    J Oral Pathol Med; 2023 Aug; 52(7):610-618. PubMed ID: 37098725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
    J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve Outcomes.
    Lee RH; Kang H; Yom SS; Smogorzewska A; Johnson DE; Grandis JR
    Clin Cancer Res; 2021 Oct; 27(19):5168-5187. PubMed ID: 34045293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FAT1 somatic mutations in head and neck carcinoma are associated with tumor progression and survival.
    Lin SC; Lin LH; Yu SY; Kao SY; Chang KW; Cheng HW; Liu CJ
    Carcinogenesis; 2018 Dec; 39(11):1320-1330. PubMed ID: 30102337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical implication of genetic intratumor heterogeneity for targeted therapy in head and neck cancer.
    Gram SB; Alosi D; Bagger FO; Østrup O; von Buchwald C; Friborg J; Wessel I; Vogelius IR; Rohrberg K; Rasmussen JH
    Acta Oncol; 2023 Dec; 62(12):1831-1839. PubMed ID: 37902999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.